Xueping Qu serves as a Principal Scientist and Biomarker Team Leader in Translational Medicine Oncology at Genentech, where she leverages her extensive 17 years of experience in the biotechnology industry to drive innovative therapies for cancer patients. With a strong focus on precision medicine, Xueping...
Xueping Qu serves as a Principal Scientist and Biomarker Team Leader in Translational Medicine Oncology at Genentech, where she leverages her extensive 17 years of experience in the biotechnology industry to drive innovative therapies for cancer patients. With a strong focus on precision medicine, Xueping is recognized for her leadership in cross-functional biomarker teams, guiding projects from Pre-IND stages through to Phase 3 clinical trials in solid tumors. Her expertise encompasses a wide array of biomarker-related science, including the development of predictive and pharmacodynamic biomarkers, patient selection strategies, and companion diagnostic (CDx) assay development.
At Genentech, Xueping has been instrumental in shaping the strategic direction of clinical development programs, ensuring that biomarker insights are effectively integrated into the drug development process. Her work on rational drug combinations and understanding drug resistance mechanisms has been pivotal in enhancing the efficacy of targeted therapies and cancer immunotherapy. Xueping’s proficiency in assay development, including techniques such as Western Blotting and SDS-PAGE, complements her role in preclinical biomarker identification, allowing her to translate complex biological data into actionable clinical strategies.
Her collaborative approach and excellent interpersonal skills foster a dynamic environment where cross-disciplinary teams can thrive, ultimately accelerating the path from laboratory discoveries to impactful patient treatments. As a thought leader in biomarker discovery and clinical development, Xueping Qu continues to make significant contributions to advancing the field of oncology, embodying a commitment to improving patient outcomes through innovative science.
